Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,433 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Terminated Phase 1 Interventional

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

NCT01729104
View directory record Official record
Conditions
Lymphoma
Interventions
Carfilzomib, Lenalidomide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT06422520
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BGB-C354, Tislelizumab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention

NCT03895320
View directory record Official record
Conditions
Sexual Behavior, Unprotected Sex, Gonorrhea, Chlamydia, Trichomonas, Sexually Transmitted Diseases, Adolescent Behavior, Self Evaluation
Interventions
Sexual Health Risk Assessment, Sexual Health Score, Sexual Health Messaging, Water SSB Quiz, Water SSB Score, Water SSB Messaging, STI Screening
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
14 Years to 26 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 24, 2026, 5:46 PM EDT
Completed No phase listed Observational

Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome

NCT00238810
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 24, 2026, 5:46 PM EDT
Withdrawn Phase 1 Interventional

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

NCT03768310
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions
CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 24, 2026, 5:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397
View directory record Official record
Conditions
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
Interventions
HST-1011, Cemiplimab
Drug · Biological
Lead sponsor
HotSpot Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Sarasota, Florida • Las Vegas, Nevada • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

NCT01075113
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, vorinostat
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 24, 2026, 5:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT02758990
View directory record Official record
Conditions
Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds, Dyspnea, Headache, Migraine Disorders, Arthritis, Arthralgia, Anxiety, Sleep Initiation and Maintenance Disorders, Sleep Deprivation
Interventions
Vitamin A, Vitamin B6, Vitamin C, Nicotinamide, Vitamin D3, Vitamin E, Broccoli, Spinach, Caffeine, Coffee, Axon Eyewear, Chocolate
Dietary Supplement · Other · Device
Lead sponsor
Verifomics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Lung Cancer Exercise Training Study

NCT01068210
View directory record Official record
Conditions
Lung Cancer
Interventions
Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

NCT05270213
View directory record Official record
Conditions
Advanced Cancer
Interventions
RBS2418, Pembrolizumab, Other approved anti-cancer therapy
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910
View directory record Official record
Conditions
Pemphigus
Interventions
Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

NCT02833883
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer
Interventions
Enzalutamide, CC-115
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

NCT04827745
View directory record Official record
Conditions
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)
Interventions
BLINCYTO (Blinatumomab)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT02890329
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Decitabine, Ipilimumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
11
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

NCT04926051
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986172, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

NCT05787002
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia

NCT02379156
View directory record Official record
Conditions
Tetraplegia, Hypothermia, Mild Cognitive Impairment
Interventions
Midodrine Hydrochloride, Cool Temperature
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 68 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 24, 2026, 5:46 PM EDT
Terminated Not applicable Interventional

Step Down Colon Cancer Risk

NCT01476631
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
Walking
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 24, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01585805
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

NCT00996268
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
GSK2212836
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 24, 2026, 5:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450
View directory record Official record
Conditions
Advanced Solid Tumors Cancer, MSI-H Cancer
Interventions
NDI-219216
Drug
Lead sponsor
Nimbus Wadjet, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

NCT01148862
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
The MiniMed Paradigm® X54 System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Escondido, California • Stanford, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

NCT05835362
View directory record Official record
Conditions
ADHD
Interventions
Question Prompt List, Video Only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 24, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

NCT07283263
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-985521, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 5:46 PM EDT